112 related articles for article (PubMed ID: 33446653)
1. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Wang YX; Zhang X; Ma QY; Hu LD; Zhang X; Wang Y; Xu L; Yang CH; Tan C; Kong XY; Ding J; Meng LH
Cell Death Dis; 2021 Jan; 12(1):85. PubMed ID: 33446653
[TBL] [Abstract][Full Text] [Related]
2. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.
Xing H; Gao M; Wang Y; Zhang X; Shi J; Wang X; Liu X; Ma Q; Kong X; Yang C; Ding J; Meng L
Clin Transl Med; 2022 May; 12(5):e835. PubMed ID: 35604910
[TBL] [Abstract][Full Text] [Related]
4. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
[TBL] [Abstract][Full Text] [Related]
5. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
[TBL] [Abstract][Full Text] [Related]
6. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
[TBL] [Abstract][Full Text] [Related]
7. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors.
Zhang X; Wang Y; Zhang X; Shen Y; Yang K; Ma Q; Qiao Y; Shi J; Wang Y; Xu L; Yang B; Ge G; Hu L; Kong X; Yang C; Chen Y; Ding J; Meng L
Signal Transduct Target Ther; 2023 Apr; 8(1):153. PubMed ID: 37041169
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
Wang Y; Li X; Liu X; Chen Y; Yang C; Tan C; Wang B; Sun Y; Zhang X; Gao Y; Ding J; Meng L
Cancer Biol Med; 2019 Feb; 16(1):66-83. PubMed ID: 31119047
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
11. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Chu J; Niu X; Chang J; Shao M; Peng L; Xi Y; Lin A; Wang C; Cui Q; Luo Y; Fan W; Chen Y; Sun Y; Guo W; Tan W; Lin D; Wu C
Theranostics; 2020; 10(8):3488-3502. PubMed ID: 32206103
[No Abstract] [Full Text] [Related]
12. AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway.
Zhang ZF; Huang TJ; Zhang XK; Xie YJ; Lin ST; Luo FF; Meng DF; Hu H; Wang J; Peng LX; Qian CN; Cheng C; Huang BJ
J Cell Mol Med; 2020 Sep; 24(17):9999-10012. PubMed ID: 32678482
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.
Yu VZ; Wong VC; Dai W; Ko JM; Lam AK; Chan KW; Samant RS; Lung HL; Shuen WH; Law S; Chan YP; Lee NP; Tong DK; Law TT; Lee VH; Lung ML
Gastroenterology; 2015 Dec; 149(7):1825-1836.e5. PubMed ID: 26302489
[TBL] [Abstract][Full Text] [Related]
14. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
15. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer.
Hu X; Zhai Y; Kong P; Cui H; Yan T; Yang J; Qian Y; Ma Y; Wang F; Li H; Cheng C; Zhang L; Jia Z; Li Y; Yang B; Xu E; Wang J; Yang J; Bi Y; Chang L; Wang Y; Zhang Y; Song B; Li G; Shi R; Liu J; Zhang M; Cheng X; Cui Y
Cancer Lett; 2017 Jul; 397():83-93. PubMed ID: 28366557
[TBL] [Abstract][Full Text] [Related]
16. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.
Ma S; Bao JYJ; Kwan PS; Chan YP; Tong CM; Fu L; Zhang N; Tong AHY; Qin YR; Tsao SW; Chan KW; Lok S; Guan XY
Gastroenterology; 2012 Sep; 143(3):675-686.e12. PubMed ID: 22705009
[TBL] [Abstract][Full Text] [Related]
17. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
Chen L; Bi S; Hou J; Zhao Z; Wang C; Xie S
Cell Commun Signal; 2019 Apr; 17(1):31. PubMed ID: 30971268
[TBL] [Abstract][Full Text] [Related]
18. Solute Carrier Family 39 Member 6 Gene Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-Kinase Signaling, and Up-regulating Genes That Regulate Metastasis.
Cheng X; Wei L; Huang X; Zheng J; Shao M; Feng T; Li J; Han Y; Tan W; Tan W; Lin D; Wu C
Gastroenterology; 2017 Jun; 152(8):1985-1997.e12. PubMed ID: 28209530
[TBL] [Abstract][Full Text] [Related]
19. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
20. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
